Screener
Phathom Pharmaceuticals, Inc. PHAT Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Phathom Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Phathom Pharmaceuticals, Inc.’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 7:05 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-324867
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $182,478 | $129,972 |
| Prepaid expenses and other current assets | 8,302 | 15,353 |
| Accounts receivable, net | 97,422 | 78,129 |
| Inventory | 7,713 | 5,518 |
| Total current assets | 295,915 | 228,972 |
| Property and equipment, net | 971 | 1,064 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Phathom Pharmaceuticals, Inc.'s cash & equivalents?
- Phathom Pharmaceuticals, Inc. (PHAT) reported cash & equivalents of $182.48M in Q2 2026.
- How has Phathom Pharmaceuticals, Inc.'s cash & equivalents changed year-over-year?
- Phathom Pharmaceuticals, Inc.'s cash & equivalents increased by 22.0% year-over-year, from $149.57M to $182.48M.
- What is the long-term trend for Phathom Pharmaceuticals, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Phathom Pharmaceuticals, Inc.'s cash & equivalents has grown at a -14.7% compound annual growth rate (CAGR), from $287.5M to $129.97M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Phathom Pharmaceuticals, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude